GO
Loading...

Sanofi SA

More

  • *Sanofi, Regeneron vying with drugs from Amgen and Pfizer. BARCELONA, Aug 31- An experimental cholesterol-lowering drug from Sanofi and Regeneron Pharmaceuticals roughly halved the number of heart attacks and strokes in a clinical trial, researchers reported on Sunday.

  • WASHINGTON, Aug 27- International Business Machines Corp on Wednesday launched a computer system that can quickly identify patterns in massive amounts of data, an ability that IBM said should hasten breakthroughs in science and medical research. IBM will make the service available through the cloud.

  • *Drug has orphan drug status in US, EU and Japan. Aug 20- Amicus Therapeutics Inc moved a step closer to bringing its first drug to the market after trial results paved the way for its lead drug to become the first oral treatment for patients with a disorder that causes an abnormal build-up of fat.

  • Aug 20- Amicus Therapeutics Inc said its experimental drug was as effective as enzyme replacement therapies after 18 months in patients with Fabry disease, an inherited disorder that leads to the abnormal build-up of fat. The company's stock rose 38 percent in premarket trading on Wednesday after the results of the second late-stage trial were released.

  • FDA approves new drug for rare genetic disease Tuesday, 19 Aug 2014 | 6:00 PM ET

    Cerdelga is from Genzyme, the specialty drugmaker that introduced the first drug for Gaucher's disease 20 years ago. The oral treatment could serve as an alternative to Genzyme's best-selling drug Cerezyme, which is given intravenously. Genzyme says it will soon release pricing for its new drug.

  • NORWICH, England, Aug 17- Pampering leafcutter ants with fragrant rose petals and fresh oranges may seem an unlikely way to rescue modern medicine, but scientists at a lab in eastern England think it's well worth trying.

  • NEW YORK, Aug 13- Biotechnology company InterMune Inc is working with financial advisers to evaluate strategic options as it braces for potential takeover interest from larger drugmakers, people familiar with the matter said.

  • NEW YORK, Aug 11- U.S. stocks rose broadly on Monday, extending Friday's sharp rally as recent uncertainty pertaining to Ukraine and the Middle East appeared to ease, while Priceline rallied on its results.

  • BUSINESS-NEWS-SCHEDULE AT 1430 GMT / 10.30 AM ET Monday, 11 Aug 2014 | 11:31 AM ET

    NEW YORK- Global stocks bounce after recent sell-offs and core government debt prices fall as markets see receding risks of direct conflict between Russia and Ukraine while Middle East tensions diminish.

  • *MannKind signs agreement with Sanofi, shares jump. NEW YORK, Aug 11- U.S. stocks rose on Monday, extending Friday's sharp rally as concerns eased over both Federal Reserve monetary policy and the tense situation between Russia and Ukraine.

  • *MannKind signs agreement with Sanofi, shares jump. NEW YORK, Aug 11- U.S. stock index futures pointed to a higher open on Monday, suggesting that Friday's sharp rally could continue as it appeared less likely that the tense situation between Russia and Ukraine would escalate.

  • US STOCKS-Futures higher as Ukraine tensions ease Monday, 11 Aug 2014 | 7:35 AM ET

    *MannKind signs agreement with Sanofi, shares jump. NEW YORK, Aug 11- U.S. stock index futures were higher on Monday, indicating that Friday's sharp rally could continue as it appeared less likely that the tense situation between Russia and Ukraine would escalate.

  • *Sanofi, MannKind aim to launch Afrezza in U.S. in Q1 2015. PARIS/ LONDON, Aug 11- French drugmaker Sanofi is betting on inhaled insulin as an alternative option to daily injections for diabetics by signing a worldwide licensing agreement with MannKind Corp worth up to $925 million.

  • NEW YORK, Aug 5- Belgian pharmaceutical company UCB is exploring a sale of its Kremers Urban Pharmaceuticals Inc division, a U.S. specialty generics business that could fetch as much as $2 billion, according to people familiar with the matter. Other companies that are exploring similar sales include GlaxoSmithKline Plc, Sanofi SA and Merck& Co Inc..

  • Aug 5- Regeneron Pharmaceuticals Inc on Tuesday reported higher-than-expected quarterly revenue and earnings on surging demand for its Eylea treatment for macular degeneration, and stuck to its full-year sales forecast for the drug.

  • *Shares in Adidas and Banco Espirito Santo slump. LONDON, July 31- European shares fell sharply on Thursday, with the euro zone's blue-chip index slipping to a three-month low, on concerns of an earlier than expected interest rate hike in the Uniteed States and a debt default by Argentina.

  • European shares hit 2-week low, Adidas slumps Thursday, 31 Jul 2014 | 7:39 AM ET

    *Adidas, Banco Espirito Santo shares slump. LONDON/ PARIS, July 31- Europe's FTSEurofirst 300 index of top shares slipped to a two-week low on Thursday, led lower by Adidas after the group warned about business in Russia, while Argentina's default also rattled investors.

  • Adidas pulls European stocks lower Thursday, 31 Jul 2014 | 4:29 AM ET

    PARIS, July 31- European shares fell in early trade on Thursday, led by Adidas after the group warned about business in Russia, while Argentina's default also rattled investors. Spanish stocks also underperformed, with Madrid's IBEX dropping 1.5 percent, as traders cited worries over Spanish companies' exposure to Latin America after Argentina's debt default.

  • PARIS, July 31- European shares were steady in early trade on Thursday as investors combed through a batch of corporate results from blue-chips such as Sanofi, Anheuser-Busch InBev and Royal Dutch Shell.

  • PARIS, July 31- French drugmaker Sanofi raised its full-year profit forecast on Thursday along with a set of stronger than expected quarterly earnings driven by its rare disease and diabetes businesses and higher sales in emerging markets.